Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Enterprise Value: 2009-2025

Historic Enterprise Value for Amicus Therapeutics (FOLD) over the last 16 years, with Sep 2025 value amounting to $2.2 billion.

  • Amicus Therapeutics' Enterprise Value fell 25.80% to $2.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year decrease of 32.76%. This contributed to the annual value of $2.6 billion for FY2024, which is 33.81% down from last year.
  • According to the latest figures from Q3 2025, Amicus Therapeutics' Enterprise Value is $2.2 billion, which was up 41.19% from $1.5 billion recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Enterprise Value registered a high of $3.9 billion during Q4 2023, and its lowest value of $1.5 billion during Q2 2025.
  • For the 3-year period, Amicus Therapeutics' Enterprise Value averaged around $2.8 billion, with its median value being $2.9 billion (2023).
  • As far as peak fluctuations go, Amicus Therapeutics' Enterprise Value plummeted by 50.56% in 2021, and later rose by 29.42% in 2022.
  • Over the past 5 years, Amicus Therapeutics' Enterprise Value (Quarterly) stood at $2.7 billion in 2021, then increased by 14.66% to $3.1 billion in 2022, then increased by 23.53% to $3.9 billion in 2023, then slumped by 33.81% to $2.6 billion in 2024, then decreased by 25.80% to $2.2 billion in 2025.
  • Its Enterprise Value stands at $2.2 billion for Q3 2025, versus $1.5 billion for Q2 2025 and $2.2 billion for Q1 2025.